Search Results 1071-1080 of 15448 for alt

1. Predicting Nonalcoholic Steatohepatitis With Advanced Fibrosis Outcomes - Mayo Clinic

   The F4 score is based on LSM, platelets, AST:ALT ratio, diabetes status and sex; many of these parameters are accepted by regulatory standards to represent a ...

2. A Study of Pembrolizumab Alone or Combined with CC-486 for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer - Mayo Clinic

   ... (ALT) < 2.0 x ULN or ≤ 5 X ULN with liver metastases; International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 X ULN unless receiving ...

3. A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole - Mayo Clinic

   * Subject has abnormal liver test parameters: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \> 10-fold the upper limit of normal ...

4. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

   ... ALT (SGPT) ≤ 1.5x institutional ULN unless liver metastases are present in which case it must be ≤ 5x ULN. The effects of abiraterone, olaparib or the ...

5. A Study of STX-0712 in Patients with Advanced Hematologic Malignancies - Mayo Clinic

   In patients with CMML or AML with potential liver involvement, AST/ALT ≤5 x ULN; Serum bilirubin – total ≤1.5 x ULN (unless due to Gilbert's syndrome ...

6. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer - Mayo Clinic

   Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ...

7. Benralizumab for Eosinophilic Esophagitis - Mayo Clinic

   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the upper limit of normal (ULN), confirmed by repeated testing during the ...

8. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

   AST and ALT ≤ 3.0 x IULN o. Patients must not have chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of ...

9. A Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) - Mayo Clinic

   aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) ≤5 × ULN. 2. Renal: Calculated creatinine clearance ≥60 mL/min. Exclusion Criterion for ...

10. Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

    Alanine aminotransferase (ALT) <=2.5X ULN;; Estimated glomerular filtration rate (eGFR) >=30 milliliter per minute per 1.73 meter square (mL/min/m^2);; Spot ...